Tuesday, July 3, 2007


Entropic Completes RF Magic Acquisition
San Diego-based Entropic Communications announced Monday that it has completed its acquisition of San Diego-based RF Magic. Financial terms of the deal were not disclosed. The acquisition was originally announced in April. Entropic said that the merger of the two companies will allow it to provide a more comprehensive product portfolio, broader technical capabilities, and scale. RF Magic has received venture funding from Anthem Ventures, Comcast Interactive Capital, Conexant, EchoStar, Finaventu (More info...)
posted on Tuesday, July 3, 2007(Full story)

CSC Completes Covansys Acquisition
El Segundo-based Computer Sciences has completes its acquisition of Covansys, the firm said Monday afternoon. Covansys is a provider of outsourcing for the healthcare, financial services, and other indutries. The deal was worth $1.3B in cash. Covansys will add about 8,200 employees, with the majority, 6,000, in India, to CSC's workforce. CSC said it now employs approximately 14,000 people in India. Computer Sciences provides outsourcing of information technology (IT) in various industries and go (More info...)
posted on Tuesday, July 3, 2007(Full story)

Acacia Taps Microsoft For VP
Newport Beach-based Acacia Research, a firm that licenses and acquires patents, said today that it has hired Jonathan Taub as Vice President. Taub joins Acacia from Microsoft, where he was the firm's Director of Strategic Alliances for the Mobile and Embedded Devices division. Taub has also served at Nortel Networks, and served as an intellectual property and corporate law Associate at Covington & Burling. Acacia Research purchases patents and licenses those patents to other companies.
posted on Tuesday, July 3, 2007(Full story)

AVANIR Pharmaceuticals Sells Compound
Aliso Viejo-based AVANIR Pharmaceuticals said today that it has sold its antipsychotic compound FazaClo to Azur Pharma, an Irish pharmaceuticals firm, in a deal worth $54M. AVANIR said that it will use the proceeds of the sale to fund continued development of Zenvia, the company's treatment for involuntary emotional expression disorder (IEED) and diabetic peripheral neuropathic (DPN) pain. The deal includes $42M in cash plus up to $10M in contingent payments and $2M in royalties. The firm acquir (More info...)
posted on Tuesday, July 3, 2007(Full story)